… HPV vaccine. In an effectiveness study covering the entire Swedish population, HPV vaccine
effectiveness against genital warts … <14 years) and vaccine effectiveness decreased with …

… before HPV vaccination show an increasing trend. Australia began offering HPV vaccination
free of … in the incidence of GWs among women in the target age group for HPV vaccination. …

… quadrivalent HPV vaccine were effective against genital warts in our population. Moreover,
with low vaccine coverage the incidence of genital warts decreased only in the vaccinated. …

… HPV-related disease. We provide nationwide, real-world data on the risk of genital warts (GWs)
after <3 vaccine … against GWs with the quadrivalent HPV vaccine (HPV types 6, 11, 16, …

… To assess the effectiveness of the HPV vaccines in preventing genital warts (GW) in women
aged 14–23 years and to estimate the incidence of GW in the whole population aged from …

… Approximately 70% of cervical cancer is caused by infection with HPV types 16 and 18 and
∼90% of genital warts are caused by HPV types 6 and 11. The quadrivalent HPV vaccine …

… In this study, we describe the ongoing population effect of the quadrivalent human
papillomavirus vaccination programme on genital warts in Australian patients five years after the …

… of HPV vaccine in preventing the relapse of ano-genital warts. The results suggest that HPV
vaccination does not provide secondary benefit in patients with previous ano-genital warts. …

… of a nonavalent HPV vaccination for treatment of genital warts because the vaccine may
be beneficial as an alternative noninvasive treatment of recalcitrant genital warts. However, …

… human papillomavirus (HPV) vaccine has been assumed to give protection against genital
warts (GW) as well as cervical cancer. Our main question was whether HPV vaccine has any …